No data is available for display.
No data is available for display.


TEVA PHARMACEUTICAL INDUSTRIES LTD filed this Form 6-K on 04/26/2011








Washington, D.C. 20549





Report of Foreign Private Issuer



Pursuant to Rule 13a‑16 or 15d‑16

under the Securities Exchange Act of 1934




For the month of April 2011


Commission File Number            0-16174        




          Teva Pharmaceutical Industries Limited          

(Translation of registrant's name into English)



5 Basel Street, P.O. Box 3190

          Petach Tikva 49131  Israel          


(Address of principal executive offices)




Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:



Form 20-F        X       

Form 40-F                   

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):                             


Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):                              

















Teva Provides Update on Company Activities


Teva Pharmaceutical Industries Ltd. has resumed manufacturing at its Irvine, California injectable products manufacturing facility. The facility has been under a voluntary manufacturing and distribution hold since April of 2010. The Company believes this is a significant step for improving its product availability for the U.S. injectable market.


The Company has also submitted a complete response to the FDA's January 31, 2011 warning letter relating to its oral solid dose manufacturing facility in Jerusalem, following the implementation of corrective actions.





Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,450 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics. Teva's leading innovative product, Copaxone®, is the number one prescribed treatment for relapsing-remitting multiple sclerosis. Teva employs approximately 40,000 people around the world and reached $16.1 billion in net sales in 2010.


















Teva Pharmaceutical Industries Ltd. Web Site:





Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.








By: /s/  Eyal Desheh

Name: Eyal Desheh
Title: Chief Financial Officer


Date April 21, 2011